Keywords

• 124782-63-4
• drug impurity
• Epalrestat (Z, Z)-Isomer

Quick Details

• ProName: Epalrestat (Z, Z)-Isomer
• CasNo: 124782-63-4
• Molecular Formula: C15H13NO3S2
• Appearance: solid
• Application: for drug impurity for drug standards,f...
• DeliveryTime: 1-2 weeks
• PackAge: 10mg/25mg/50mg/100mg/1000mg/5000mg
• Port: SHENZHEN or SHANGHAI
• ProductionCapacity: 5000 Metric Ton/Year
• Purity: 95%+ or 98%+
• Storage: short-term storage normal temperature....
• Transportation: express and sea transport and air frei...
• LimitNum: 25 Milligram
• Moisture Content: within 3%
• Impurity: within 5%

Superiority

Our products are mainly drug impurity reference products, drug standards, analytical chemistry, standard substances, organic chemical synthesis, chemical custom synthesis. For impurity localization, quantification, and quality control in drug development processes. Our laboratory area is more than 5000 square meters, we have more than 20 analytical instruments such as HPLC and MS/LC-MS/GC-MS, we also have TGA, IR and other testing instruments. We have the most advanced SFC preparation separation equipment. We can provide a full range of impurity reference/standard products required for drug development. Most of the impurities are synthesized through the process, there are also many items of impurities can not be obtained by synthetic means, need to be obtained through raw materials, intermediates, crude products or side reactions contained in the trace target compounds, Hubei Moke has a professional impurity preparation and separation technology team, equipped with professional SFC preparation and separation equipment. It can carry out efficient and accurate separation of impurities for complex projects, and solve the problem of impurity preparation for customers.
 

1. We integrate R&D, production and sales. A 5,000-square-meter high-standard bio-intelligent manufacturing base can ensure high quality and fast delivery of products. The professional sales team ensures that you don't need to worry about pre-sales and after-sales.

2. We focus on pharmaceutical standards, pharmaceutical intermediates, pharmaceutical impurity controls, peptide customization, our own laboratory, and undertake customized synthesis projects.

3. We offer products from gram grade to g grade, in addition, some product specifications and packaging can be customized.

4. We have been deeply engaged in the pharmaceutical field for ten years and have rich experience. At present, customers are all over the world, and have been highly recognized and trusted by customers.

5. We can provide a variety of safe ways to transport goods for you to choose.

Details

Epalrestat (Z, Z)-Isomer

Product Information

• Product Code：E022004

• English Name：Epalrestat (Z, Z)-Isomer

• English Alias：2-((Z)-5-((Z)-2-methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid

• CAS No.：124782-63-4

• Molecular Formula：CHNOS

• Molecular Weight：319.4

Advantages

• High-Purity Reference Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and X-ray crystallography for stereostructure, suitable for cis-isomer impurity analysis of Epalrestat.

• Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.1% in methanol-water solution within 6 months.

Applications

• Quality Control Testing：Used for UPLC-MS/MS detection of (Z,Z)-isomer in Epalrestat API and formulations, controlling impurity content to meet ICH Q3A standards (≤0.1%).

• Process Optimization Research：Monitors cis-isomer formation during Epalrestat synthesis, reducing generation by >50% by adjusting condensation temperature (e.g., 0-5℃) and reaction time.

• Method Validation：Serves as a chiral standard for developing isomer separation methods, verifying UPLC resolution (≥3.0) and LOD (0.005 ng/mL).

Background Description

Epalrestat, an aldose reductase inhibitor, is used for treating diabetic neuropathy. The (Z,Z)-isomer, as a cis-impurity, may originate from stereoselective side reactions during allylation in synthesis or configuration conversion under high temperature and acidic conditions. Its thioxothiazolidine ring and phenyl structure may affect drug stability and efficacy. With stricter EMA requirements for chiral impurity control, studying such cis-impurities is key to ensuring drug quality.

Research Status

• Detection Technology：UPLC-MS/MS with Chiralpak IA column (1.7μm) and n-hexane-ethanol (85:15) gradient elution achieves separation within 4.5 minutes, with LOD of 0.002 ng/mL for trace chiral impurity analysis.

• Formation Mechanism：Formed by reaction of 2-methyl-3-phenylacrolein with thioxothiazolidinone under alkaline conditions (e.g., sodium carbonate catalysis). Using enzymatic catalysis (e.g., lipase) or asymmetric catalysis reduces cis-impurity formation by >80%.

• Safety Evaluation：In vitro cytotoxicity shows IC of 182.5 μM against HepG2 cells (Epalrestat IC=12.6 μM), with low toxicity but requiring ≤0.1% limit. Accelerated stability testing is ongoing to monitor configuration conversion rates under different pH conditions.